MRUS - メルス (Merus N.V.) メルス

 MRUSのチャート


 MRUSの企業情報

symbol MRUS
会社名 Merus NV (メルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include among others MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.   メルスはオランダのバイオ医薬品企業。臨床段階で、主に二重特異性抗体医薬の開発に焦点を当てる。同社パイプラインは、がん腫瘍細胞の生存と成長を引き起こすレセプタ―をブロックして、腫瘍を根絶するためにキラ―細胞を起動させることによって、患者の免疫機能に働きかける。前臨床試験において効果を示す。本社はユトレヒト。   Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
本社所在地 Yalelaan 62 Utrecht 3584 CM NLD
代表者氏名 Mark T. Iwicki Mark T. Iwicki
代表者役職名 Chairman of the Supervisory Board
電話番号 +31 30-253-8800
設立年月日 37773
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 83人
url www.merus.nl
nasdaq_url https://www.nasdaq.com/symbol/mrus
adr_tso
EBITDA EBITDA(百万ドル) -44.48295
終値(lastsale) 18.18
時価総額(marketcap) 411464304
時価総額 時価総額(百万ドル) 366.52000
売上高 売上高(百万ドル) 27.34463
企業価値(EV) 企業価値(EV)(百万ドル) 127.73490
当期純利益 当期純利益(百万ドル) -49.48767
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Merus NV revenues increased 63% to EUR16.5M. Net loss decreased 67% to EUR13M. Revenues reflect Collaboration income increase from EUR2.4M to EUR7.2M Up-front payment amortization increase of 32% to EUR9.1M. Lower net loss reflects Net loss on foreign exchange decrease from EUR12M (expense) to EUR0K Interest expense decrease of 100% to EUR1K (expense).

 MRUSのテクニカル分析


 MRUSのニュース

   Merus Stock: Precision Oncology Pioneer Executes In The Clinic (NASDAQ:MRUS)  2022/06/30 15:33:38 Seeking Alpha
Merus shares have risen by 40% since my 2020 ROTY update, but have lost a third of their value in 2022. Read more to find out why MRUS stock is a buy.
   Why Buy Stock In Merus N.V. (MRUS)?  2022/06/07 16:00:00 Marketing Sentinel
Merus N.V. (NASDAQ:MRUS) has a beta value of 1.11 and has seen 0.7 million shares traded in the recent trading session. The company, currently valued at $836.21M, closed the recent trade at $22.21 per share which meant it gained $0.84 on the day or 3.93% during that session. The MRUS stock price is -48.99% off … Why Buy Stock In Merus N.V. (MRUS)? Read More »
   Needham Says Merus'' ASCO Update On Zeno ''Positive''  2022/06/06 18:54:18 Benzinga
Needham writes that Merus NV (NASDAQ: MRUS ) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. The analyst says that the data was in line with what was presented in ASCO 2021 with no surprises but noted that Merus''s undisclosed discussions with the FDA is the only missing piece of … Full story available on Benzinga.com
   Merus N.V. (MRUS) Investor Presentation - Slideshow (NASDAQ:MRUS)  2022/05/24 19:05:27 Seeking Alpha
The following slide deck was published by Merus N.V.
   Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight  2022/05/24 17:00:00 Benzinga
New York, USAMetastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | De, May 24, 2022 (GLOBE NEWSWIRE) -- Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight DelveInsight''s '' Metastatic Breast Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Breast Cancer pipeline domain. Key Takeaways from the Metastatic Breast Cancer Pipeline Report DelveInsight''s Metastatic Breast Cancer Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Metastatic Breast Cancer treatment.
   Why Buy Stock In Merus N.V. (MRUS)?  2022/06/07 16:00:00 Marketing Sentinel
Merus N.V. (NASDAQ:MRUS) has a beta value of 1.11 and has seen 0.7 million shares traded in the recent trading session. The company, currently valued at $836.21M, closed the recent trade at $22.21 per share which meant it gained $0.84 on the day or 3.93% during that session. The MRUS stock price is -48.99% off … Why Buy Stock In Merus N.V. (MRUS)? Read More »
   Needham Says Merus'' ASCO Update On Zeno ''Positive''  2022/06/06 18:54:18 Benzinga
Needham writes that Merus NV (NASDAQ: MRUS ) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. The analyst says that the data was in line with what was presented in ASCO 2021 with no surprises but noted that Merus''s undisclosed discussions with the FDA is the only missing piece of … Full story available on Benzinga.com
   Merus N.V. (MRUS) Investor Presentation - Slideshow (NASDAQ:MRUS)  2022/05/24 19:05:27 Seeking Alpha
The following slide deck was published by Merus N.V.
   Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight  2022/05/24 17:00:00 Benzinga
New York, USAMetastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | De, May 24, 2022 (GLOBE NEWSWIRE) -- Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight DelveInsight''s '' Metastatic Breast Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Breast Cancer pipeline domain. Key Takeaways from the Metastatic Breast Cancer Pipeline Report DelveInsight''s Metastatic Breast Cancer Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Metastatic Breast Cancer treatment.
   Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting  2022/04/27 20:01:00 Benzinga
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS ) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 3-7, 2022. The presentation will highlight updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), in NRG1 fusion positive (NRG1+) cancer. Merus is currently enrolling patients into the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer. Oral Presentation: Title: Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers Lead Author: Alison Schram, MD, Memorial Sloan Kettering Cancer Center, NY Abstract #: 105 Session Title: Clinical Science Symposium/ Bispecifics: Are Two Better Than One?
   Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers  2021/06/04 19:37:07 Benzinga
Eli Lilly & Cos (NYSE: LLY ) R&D partner Merus N.V. (NASDAQ: MRUS ) have revealed some new data at ASCO21 for an in-house program, zenocutuzumab (Zeno), in patients with NRG1+ cancers. As of April 13 cutoff date, Zeno induced partial responses in 13 of 45 patients, with an overall response rate of 29%. Merus is evaluating the candidate in a single-arm Phase 1/2 study with Full story available on Benzinga.com
   Merus drops as RBC Capital Markets points to insufficient data in update for cancer trial  2021/05/20 20:44:37 Seeking Alpha
   Octagon Capital Advisors LP Buys Design Therapeutics Inc, Merus NV, Edgewise Therapeutics Inc, ...  2021/05/19 21:38:20 GuruFocus
Related Stocks: NGM , RCUS , DYN , DSGN , MRUS , EWTX , RXDX , RXDX , FHTX , CALT , FG ,
   Merus announces benefit of Zenocutuzumab in pancreatic cancer  2021/05/19 21:23:22 Seeking Alpha
   Merus N.V.: Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial  2021/05/13 12:05:00 FinanzNachrichten
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics),

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メルス MRUS Merus N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)